Skin and soft tissue infections are more common in children with Crohn’s disease, especially those receiving combination ...

A new study found that a combination of hormone therapy and the GLP-1 medication tirzepatide (Zepbound) led to 35% more ...

Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...

According to CNIO, among the various kinds of cancer, pancreatic cancer remains one of the deadliest and is a widely known ...

The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...

In recent years, research into cannabis and its main psychoactive ingredient, Δ⁹-tetrahydrocannabinol (THC), has unearthed ...

Spanish scientists have created a new triple drug therapy that completely cures pancreatic cancer in mice. This experimental ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...

BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...

Overall, the “Hidradenitis Suppuritiva Update 2026” session underscored a new treatment paradigm: HS care in 2026 requires early diagnosis, systemic screening, combination medical therapy, and ...

Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of ...